Opioid-Dependent Patients Respond to Therapy

September 5, 2011

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Family Practice News)

Read the full article →

Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program: A Randomized Trial.

September 5, 2011

Conclusion: Management of HIV-infected, opioid-dependent patients with a clinic-based BUP strategy facilitates access to opioid agonist therapy and improves outcomes of substance abuse treatment. Primary Funding Source: Health Resources and Services Administration Special Projects of National Significance program. PMID: 20513828 [PubMed – in process] (Source: Annals of Internal Medicine)

Read the full article →

Office-Based Treatment Effective for Opioid Dependence

September 5, 2011

Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%. (Source: Internal Medicine News)

Read the full article →

Factors associated with complicated buprenorphine inductions

September 5, 2011

Abstract: Despite data supporting its efficacy, barriers to implementation of buprenorphine for office-based treatment are present. Complications can occur during buprenorphine inductions, yet few published studies have examined this phase of treatment. To examine factors associated with complications during buprenorphine induction, we conducted a retrospective chart review of the first 107 patients receiving buprenorphine treatment […]

Read the full article →

Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers

September 5, 2011

Conclusions  These results suggest that buprenorphine and buprenorphine/naloxone have similar abuse potential in non-dependent opioid abusers, and that the addition of naloxone at these doses and in this dose ratio confers no evident advantage for decreasing the abuse potential of intramuscular or sublingual buprenorphine in this population. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1898-4Authors Angela N. […]

Read the full article →

Cost-effectiveness of extended buprenorphine–naloxone treatment for opioid-dependent youth: data from a randomized trial

September 5, 2011

Conclusions Extended BUP treatment relative to brief detoxification is cost effective in the US health-care system for the outpatient treatment of opioid-dependent youth. (Source: Addiction)

Read the full article →

SUBOXONE (Buprenorphine Hydrochloride And Naloxone Hydrochloride) Tablet [Physicians Total Care, Inc.]

September 5, 2011

Updated Date: Jul 29, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects

September 5, 2011

Abstract: Previous reports have demonstrated greater antinociception following administration of a buprenorphine/naloxone combination compared to buprenorphine alone among healthy volunteers. The aim of the current investigation was to determine whether buprenorphine antinociception could be enhanced with the addition of ultra-low dose naltrexone, using a range of dose ratios. A repeated-measures, double-blind, cross-over trial was undertaken […]

Read the full article →

Drug Treatment as HIV Prevention: Expanding Treatment Options

September 5, 2011

Abstract  Research conducted during the first 20 years of the AIDS epidemic provided a solid foundation of data supporting methadone treatment as HIV prevention. Drug users in methadone treatment were consistently found to reduce the frequency of drug use, risk behaviors, and infections. These data have been consistent over time and across cultural settings and have been […]

Read the full article →

Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia

September 5, 2011

Conclusions: In Malaysia, BUP and BNX IDU occur among heroin IDUs. The introduction of BNX and withdrawal of BUP may have helped to reduce, but did not eliminate the problems with diversion and abuse. (Source: Drug and Alcohol Dependence)

Read the full article →

← Previous Entries

Next Entries →